Tag Archives: Syndax Pharmaceuticals

Syndax Pharmaceuticals (SNDX) Gets a Buy Rating from Nomura

In a report issued on May 22, Christopher Marai from Nomura maintained a Buy rating on Syndax Pharmaceuticals (SNDX – Research Report), with a price target of $31.00. The company’s shares closed last Friday at $16.00. According to TipRanks.com, Marai

Why Did H.C. Wainwright Downgrade Syndax Pharmaceuticals’ Stock?

Syndax Pharmaceuticals (SNDX – Research Report) received a Hold rating and a $15.00 price target from H.C. Wainwright analyst Edward White today. The company’s shares closed last Friday at $15.62. According to TipRanks.com, White is a top 100 analyst with

Barclays Believes Syndax Pharmaceuticals (NASDAQ: SNDX) Still Has Room to Grow

Barclays analyst Peter Lawson maintained a Buy rating on Syndax Pharmaceuticals (SNDX – Research Report) yesterday and set a price target of $23.00. The company’s shares closed last Thursday at $20.50, close to its 52-week high of $21.97. According to

Nomura Believes Syndax Pharmaceuticals (NASDAQ: SNDX) Won’t Stop Here

In a report issued on April 28, Christopher Marai from Nomura maintained a Buy rating on Syndax Pharmaceuticals (SNDX – Research Report), with a price target of $16.00. The company’s shares closed last Thursday at $19.06, close to its 52-week

H.C. Wainwright Believes Syndax Pharmaceuticals (NASDAQ: SNDX) Still Has Room to Grow

H.C. Wainwright analyst Edward White reiterated a Buy rating on Syndax Pharmaceuticals (SNDX – Research Report) today and set a price target of $19.00. The company’s shares closed last Monday at $11.51, close to its 52-week high of $12.28. According

Syndax Pharmaceuticals (SNDX) Gets a Buy Rating from H.C. Wainwright

In a report released today, Edward White from H.C. Wainwright maintained a Buy rating on Syndax Pharmaceuticals (SNDX – Research Report), with a price target of $18.00. The company’s shares closed last Tuesday at $10.24. According to TipRanks.com, White is